Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 13, Issue 33, Pages 3378-3393Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161207782360519
Keywords
valproic acid; HDAC; differentiation; angiogenesis; combination therapy; clinical studies
Categories
Ask authors/readers for more resources
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available